Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, has appointed Richard (Rick) Barry as its new Chief Executive Officer, effective September 6, 2024. The announcement was made on September 9, 2024, following a concluded search by the company's Board of Directors. Rick Barry, who has been a director at Cassava since June 2021 and served as the Executive Chairman since July 17, 2024, brings extensive experience in investment management and has held director roles at other public companies. Concurrently, the company has appointed Claude Nicaise, M.D., as its Chairman, separating the roles of CEO and Chairman to adhere to good governance practices. Dr. Nicaise, with a history of clinical and regulatory leadership resulting in new drug approvals, has been a director at Cassava since December 2023. The company also highlighted the ongoing Phase 3 trials of its Alzheimer's treatment, simufilam, with expected results by the end of 2024 and mid-2025.

Cassava Sciences, Inc., a biotechnology company focusing on Alzheimer's disease, has appointed Richard (Rick) Barry as its new Chief Executive Officer, effective September 6, 2024. The announcement was made on September 9, 2024, following a concluded search by the company's Board of Directors. Rick Barry, who has been a director at Cassava since June 2021 and served as the Executive Chairman since July 17, 2024, brings extensive experience in investment management and has held director roles at other public companies. Concurrently, the company has appointed Claude Nicaise, M.D., as its Chairman, separating the roles of CEO and Chairman to adhere to good governance practices. Dr. Nicaise, with a history of clinical and regulatory leadership resulting in new drug approvals, has been a director at Cassava since December 2023. The company also highlighted the ongoing Phase 3 trials of its Alzheimer's treatment, simufilam, with expected results by the end of 2024 and mid-2025.